Lidocaine - NanoCyte/Ferndale Laboratories

Drug Profile

Lidocaine - NanoCyte/Ferndale Laboratories

Alternative Names: Lidocaine - NanoCyte

Latest Information Update: 02 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoCyte
  • Developer Ferndale Laboratories; NanoCyte
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 02 Sep 2015 No recent reports on development identified - Phase-II for Pain in USA (Transdermal)
  • 24 Sep 2013 Biomarkers information updated
  • 10 Feb 2009 Phase-II clinical trials in Pain in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top